ArticleSexually transmitted diseases2025
Routine Pharyngeal Gonorrhea Test of Cure: Is It an Effective Cephalosporin-Resistant Gonorrhea Control Strategy?
Article in Sexually transmitted diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundThe Centers for Disease Control and Prevention recommends test of cure (TOC) for persons with pharyngeal gonorrhea (GC) 7 to 14 days after treatment. We investigated the yield and feasibility of routine pharyngeal GC TOC to detect treatment failures.
methodsDuring May 2021-July 2022, 4 US sexually transmitted disease clinics implemented pharyngeal GC TOC. Sites collected demographic, clinical, and behavioral data on all treated pharyngeal GC and positive TOC cases. Cases were dispositioned with the suspected reason for positive TOC. To assess perceived feasibility, sites participated in qualitative interviews.
resultsDuring the study period, 1968 pharyngeal GC infections were diagnosed. Among 1829 treated cases, 97.3% (n = 1777) received ceftriaxone and 45.7% (n = 836) returned for TOC, varying by site (range, 35.5%-70.8%). Among those with TOC, 4.7% (n = 39) were positive by nucleic acid amplification test. Of these, 48.7% had culture attempted; 6 positive TOCs (15.4%) were also positive by culture. Most positive TOCs (66.7%) were attributed to reinfection (n = 13) or false-positive results (n = 13). Six (15.4%) were treatment failures. Four failed recommended treatment and had a positive culture: 2 were susceptible to ceftriaxone and 2 did not have antimicrobial susceptibility results. Seven positive TOC (17.9%) had insufficient data to disposition. Sites perceived TOC to be feasible, although substantial resources were required.
conclusionRoutine pharyngeal GC TOC yielded 5% positivity, although treatment failure was rare (<1%), and no cases of cephalosporin-resistant GC were identified. Low TOC return rates, limited culture collection, and limited culture yield highlight challenges to determining the cause of a positive TOC and the limitations of TOC in identifying cephalosporin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.